Achieve Life Sciences, Inc.

QUIT Nasdaq SEC CIK 949858
Follow Achieve Life Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$12.1M +16.1% vs same quarter last year
EPS, diluted −$0.11 +60.7% vs same quarter last year
Operating cash flow −$8.4M +26.2% vs same quarter last year
Net income by quarter
−$12.4M
−$12.8M
−$12.7M
−$14.4M
−$14.7M
−$10.2M
−$74.8M
−$12.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$54.6M
FY24−$39.8M
FY23−$29.8M
FY22−$42.4M
FY21−$33.2M
FY20−$14.7M
FY19−$16.4M
FY18−$12.7M
FY17−$10.6M
FY16−$1.2M
FY15−$828K
FY14−$26.2M
FY13−$31.8M
FY12−$21.1M
FY11−$14.7M
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$49.5M
FY24-
FY23−$24.5M
FY22-
FY21-
FY20−$13.5M
FY19−$15.3M
FY18−$10.7M
FY17-
FY16−$248K
FY15−$721K
FY14−$17.4M
FY13−$36.2M
FY12−$43.8M
FY11−$20.3M